A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms.
Débora MasiniCarina PlewniaMaëlle BerthoNicolas ScalbertVittorio CaggianoGilberto FisonePublished in: Biomedicines (2021)
In Parkinson's disease (PD), a large number of symptoms affecting the peripheral and central nervous system precede, develop in parallel to, the cardinal motor symptoms of the disease. The study of these conditions, which are often refractory to and may even be exacerbated by standard dopamine replacement therapies, relies on the availability of appropriate animal models. Previous work in rodents showed that injection of the neurotoxin 6-hydroxydopamine (6-OHDA) in discrete brain regions reproduces several non-motor comorbidities commonly associated with PD, including cognitive deficits, depression, anxiety, as well as disruption of olfactory discrimination and circadian rhythm. However, the use of 6-OHDA is frequently associated with significant post-surgical mortality. Here, we describe the generation of a mouse model of PD based on bilateral injection of 6-OHDA in the dorsal striatum. We show that the survival rates of males and females subjected to this lesion differ significantly, with a much higher mortality among males, and provide a protocol of enhanced pre- and post-operative care, which nearly eliminates animal loss. We also briefly discuss the utility of this model for the study of non-motor comorbidities of PD.
Keyphrases
- mouse model
- sleep quality
- cardiovascular events
- randomized controlled trial
- type diabetes
- depressive symptoms
- risk factors
- multiple sclerosis
- spinal cord
- cardiovascular disease
- coronary artery disease
- spinal cord injury
- atrial fibrillation
- pain management
- case report
- ultrasound guided
- heart rate
- quality improvement
- chronic pain
- uric acid